Cardamone Maria Dafne, Bardella Chiara, Gutierrez Arantxa, Di Croce Luciano, Rosenfeld Michael G, Di Renzo Maria Flavia, De Bortoli Michele
Department of Medicine, Howard Hughes Medical Institute, University of California at San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093-0651, USA.
Proc Natl Acad Sci U S A. 2009 May 5;106(18):7420-5. doi: 10.1073/pnas.0903033106. Epub 2009 Apr 21.
Estrogen receptor alpha (ERalpha) and E-cadherin are primary markers of luminal epithelial breast cancer cells with E-cadherin being a main caretaker of the epithelial phenotype. E-cadherin repression is needed for cancer cells to acquire motile and invasive properties, and it is known that in ER-positive breast cancer cells, estrogen down-regulate E-cadherin gene transcription. We report here that ERalpha is bound to the E-cadherin promoter in both the presence and the complete absence of estrogen, suggesting an unexpected role for unliganded ERalpha in E-cadherin transcription. Indeed, our data reveal that activation by unliganded ERalpha and repression by estrogen-activated ERalpha require direct binding to a half-estrogen response element within the E-cadherin promoter and exchange from associated coactivators to corepressors. Therefore, these results suggest a pivotal role for unliganded ERalpha in controlling a fundamental caretaker of the epithelial phenotype in breast cancer cells. Here, we show that ERalpha-positive breast cancer T47D cells transduced with the sfRON kinase undergo a full epithelial-mesenchymal conversion and lose E-cadherin and ERalpha expression. Our data show that, although the E-cadherin gene becomes hypermethylated and heterochromatic, kinase inhibitors can restore E-cadherin expression, together with an epithelial morphology in an ERalpha-dependent fashion. Similarly, transfection of ERalpha, in the absence of ligands, was sufficient to restore E-cadherin transcription in both sfRON-T47D and other ERalpha-, E-cadherin-negative cells. Therefore, our results suggest a novel role for the ERalpha that plays the dual role of ligand-independent activator and ligand-dependent repressor of E-cadherin in breast cancer cells.
雌激素受体α(ERα)和E-钙黏蛋白是管腔上皮性乳腺癌细胞的主要标志物,其中E-钙黏蛋白是上皮表型的主要维持者。癌细胞获得运动和侵袭特性需要E-钙黏蛋白受抑制,并且已知在雌激素受体阳性的乳腺癌细胞中,雌激素会下调E-钙黏蛋白基因转录。我们在此报告,无论有无雌激素,ERα均与E-钙黏蛋白启动子结合,这表明未结合配体的ERα在E-钙黏蛋白转录中具有意想不到的作用。事实上,我们的数据显示,未结合配体的ERα激活和雌激素激活的ERα抑制都需要直接结合到E-钙黏蛋白启动子内的半雌激素反应元件,并从相关的共激活因子交换为共抑制因子。因此,这些结果表明未结合配体的ERα在控制乳腺癌细胞上皮表型的基本维持者方面具有关键作用。在这里,我们表明用sfRON激酶转导的ERα阳性乳腺癌T47D细胞经历了完全的上皮-间质转化,并失去了E-钙黏蛋白和ERα表达。我们的数据表明,虽然E-钙黏蛋白基因变得高度甲基化和异染色质化,但激酶抑制剂可以以ERα依赖的方式恢复E-钙黏蛋白表达以及上皮形态。同样,在没有配体的情况下转染ERα足以在sfRON-T47D细胞和其他ERα、E-钙黏蛋白阴性细胞中恢复E-钙黏蛋白转录。因此,我们的结果表明ERα在乳腺癌细胞中对E-钙黏蛋白起着非配体依赖激活剂和配体依赖抑制剂的双重作用,具有新的作用。